Therapeutic potential of anti-IgE antibodies

Current Opinion in Immunology

Volumn 9, Issue 6, 1997, Pages 805-813

  Heusser, Christoph ^a   Jardieu, Paula ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CGP 51901; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; ALLERGIC RHINITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; BRONCHOSPASM; CELL INFILTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG TOLERABILITY; EOSINOPHIL; HELPER CELL; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MEDIATOR RELEASE; META ANALYSIS; MOUSE; NONHUMAN; REVIEW; RHINITIS; SKIN MANIFESTATION; VACCINATION;

EID: 0031474128     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(97)80182-3     Document Type: Article

References (76)

1. Ishizaka K, Ishizaka T: Biological function of IgE antibodies and mechanisms of reaginic hypersensitivity. Clin Exp Immunol 1970, 6:25-31.
2. Paul WE: Interleukin 4: signalling mechanisms and control of T cell differentiation. Ciba Foundation Symposium 1997, 204:208-216.
3. Shimoda K, van Deursen J, Sangster MY, Sarawar SR, Carson RT, Tripp RA, Chu C, Quelle FW, Nosaka T, Vignali DA et al.: Lack of IL-4 induced Th2 responses and IgE class switching in mice with disrupted Stat 6 gene. Nature 1996, 380:630-633.
4. Hamburger RN: Inhibition of IgE binding to tissue culture cells and leukocytes by pentapeptide. Immunology 1979, 38:781-787.
5. Burt SD, Stanworth DR: Inhibition of binding of rat IgE to rat mast cells by synthetic IgE peptides. Eur J Immunol 1987, 17:437-440.
6. Helm B, Kebo D, Vercelli D, Glovsky MM, Gould H, Ishizaka K, Geha R, Ishizaka T: Blocking of passive sensitization of human mast cells and basophil granulocytes with IgE antibodies by recombinant human epsilon-chain fragment of 76 amino acids. Proc Natl Acad Sci USA 1989, 86:9465-9469.
7. Wiegand TW, Williams PB, Dreskin SC, Jouvin M-H, Kinet J-P, Tasset D: High-affinity oligonucleotides ligands to human IgE inhibit binding to Fc receptor I. J Immunol 1996, 157:221-230.
8. Haak-Frendscho M, Ridgway J, Shields R, Robbins K, German C, Jardieu P: Human IgE receptor -chain IgG chimera blocks passive cutaneous anaphylaxis reaction in vivo. J Immunol 1993, 151:351-358.
9. Chang TW, Davis FM, Sun NC, Sun CRY, MacGlashan DW, Hamilton RG: Monoclonal antibodies specific for human IgE-producing B cells: a potential therapeutic for IgE-mediated allergic diseases. Bio/Technology 1990, 8:122-126.
10. Heusser CH, Bews J, Brinkmann V, Delespesse G, Kilchherr E, Ledermann F, LeGros G, Wagner K: New concepts of IgE regulation. Inter Arch Allergy Appl Immunol 1991, 94:87-90.
11. Jardieu P: Anti-IgE therapy. Curr Opin Immunol 1995, 7:779-782.
12. Brinkmann V, Müller S, Heusser CH: T cell dependent differentiation of human B cells: direct switch from IgM to IgE, and sequential switch from IgM via IgG to IgA production. Mol Immunol 1992, 29:1159-1164.
13. Prabhu A, Ruzek MC, Kamat DM, Mathur A: Plasma IgE levels, activation marker expression, and cytokine production in non-atopic individuals. Ann! Allergy Asthma Immunol 1997, 78:45-53.
14. Peat JK, Toelle BG, Dermand J, van den Berg R, Britton WJ, Woolcock AJ: Serum IgE levels, atopy, and asthma in young adults: results from a longitudinal cohort study. Allergy 1996, 51:804-810.
15. Hook WA, Berenstein E, Basciano LA, Fox PC, Siratanian RP: Monoclonal antibodies to human IgE. Fed Proc 1981, 40:968 A 4177.
16. Baniyash M, Eshhar Z: Inhibition of IgE binding to mast cells and basophils by monoclonal antibodies to murine IgE. Eur J Immunol 1984, 14:799-807.
17. Baniyash M, Kehry M, Eshhar Z: Anti-IgE monoclonal antibodies directed at the Fc receptor binding site. Mol Immunol 1988, 25:705-711.
18. Davis FM, Gossett LA, Pinkston KL, Liou RS, Sun LK, Kim YW, Chang NT, Chang TW, Wagner K, Bews J et al.: Can anti-IgE be used to treat allergy? Springer Semin Immunopathol 1993, 15:51-73.
19. Hakimi J, Seals C, Kondas JA, Pettine L Danho W, Kochan J: The alpha subunit of the human IgE receptor (FcεRI) is sufficient for high affinity IgE binding. J Biol Chem 1990, 265:22079-22081.
20. Presta L, Shields R, O'Connell L, Lahr S, Porter J, Gorman C, Jardieu P: The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 1994, 269:26368-26373.
21. Peng C, Davis FM, Sun LK, Liou RS, Kim YW, Chang TW: A new isoform of human membrane-bound IgE J Jmmunol 1992, 148:129-136.
22. Rudolf MP, Furukawa K, Miescher S, Vogel M, Fricek F, Stadler BM: Effect of anti-IgE antibodies on FcεRI-bound IgE J Immunol 1996, 157:5646-5652.
23. Schwarzbaum S, Nissim A, Alkalay I, Ghozi M, Schindler D, Bergman Y, Eshhar Z: Mapping of murine IgE epitopes invoved in the IgE-Fc receptor interaction. Eur J Immunol 1989, 19:1015-1023.
24. Nissim A, Eshhar Z: Localization of the FeεRI binding site to the third constant domain of IgE. Internat Arch Allergy Appl Immunol 1991,94:93-95.
25. Weetall M, Shopes B, Holowka D, Baird B: Mapping the site of interaction between murine IgE and its high affinity receptor with chimeric Ig. J Immunol 1990, 145:3849-3854.
26. Vercelli D, Helm B, Marsh P, Padlan E, Geha R, Gould H: The B cell binding site on human immunoglobulin E. Nature 1989, 338:649-651.
27. Bozelka BE, McCants ML, Salvaggio JE, Lehrer SB: IgE isotype suppression in anti-ε treated mice. Immunology 1982, 46:527-532.
28. Bozelka BE, McCants ML, Salaggio JE, Lehrer SB: Effects of anti-E on total and specific IgE levels in adult mice. Internat Arch Allergy Appl Immunol 1985, 78:51-56.
29. Haba S, Nisonoff A: Effects of syngeneic anti-IgE antibodies on the development of IgE memory and on the secondary IgE response. J Immunol 1994, 152:51-57.
30. Stämpfli MR, Miescher S, Aebischer I, Zürcher AW, Stadler BM: Inhibition of human IgE synthesis by anti-IgE antibodies requires divalent recognition. Eur J Immunol 1994, 24:2161-2167.
31. Haba S, Nisonoff A: Role of antibody and T cells in the long-term inhibition of IgE synthesis. Proc Natl Acad Sci USA 1994, 91:604-608.
32. Haak-Frendscho M, Robbins K, Lyon R, Shields R, Hooley J, Schoenhoff M, Jardieu P: Administration of an anti-IgE antibody inhibits CD23 expression and IgE production in vivo. Immunology 1994, 82:306-313.
33. Lustgarten J, Waks T, Eshhar Z: Prolonged inhibition of IgE production in mice following treatment with an IgE-specific immunotoxin. Mol Immunol 1996, 33:245-251. Demonstration of long-term inhibition of the primary IgE response and partial reduction of the secondary IgE but not IgG response by the administration of a single dose of a immunotoxin composed of ricin A conjugated to a non-anaphylactogenic anti-mouse IgE antibody affecting the viability of IgE-switched B cells.
34. Chen SS, Liu FT, Katz DH: IgE class-restricted tolerance induced by neonatal administration of soluble or cell-bound IgE. Cellular mechanisms. J Exp-Med 1984, 160:953-970.
35. Haba S, Nisonoff A: Inhibition of IgE synthesis by anti-IgE: role in long-term inhibition of IgE synthesis by neonatally administered soluble IgE. Proc Natl Acad Sci USA 1990, 87:3363-3367.
36. Haba S, Nisonoff A: Prolongation of the responsiveness of newborn mice to syngeneic IgE by inhibition of IgE syntheis. Immunol Lett 1995, 47:205-208.
37. Marshall JS, Bell EB: Induction of an auto-anti-IgE response in rats. I. Effects on serum IgE concentrations. Eur J Immmunol 1985, 15:272-277.
38. Haba S, Nisonoff A: Production of syngeneic autoreactive monoclonal antibodies specific for isotypic determinants of IgE. J Immunol Methods 1987, 105:193-199.
39. Marshall JS, Bell EB: Induction of an auto-anti-IgE response in rats: III Inhibition of a specific IgE response. Immunology 1989, 66:428-433.
40. Hellman L: Profound reduction in allergen sensitivity following treatment with a novel allergy vaccine. Eur J Immunol 1994, 24:415-420.
41. Katona IM, Urban JF, Kang SS, Paul WE, Finkelman FD: IL-4 requirements for the generation of secondary in vivo IgE responses. J Immunol 1991, 146:4215-4221.
42. LeGros G, Schultze N, Wälti S, Einsle K, Finkelman F, Kosco-Vilbois M, Heusser C: The development of IgE memory B cells following primary IgE immune responses. Eur J Immunol 1996, 26:3042-3047.
43. Hausser CH, Wagner K, Bews JP, Coyle A, Bertrand C, Einsle K, Kips J, Seok-Yong E, Lefort J, Vargaftig BB: Demonstration of the therapeutic potential of non-anaphylactogenic anti-IgE antibodies in murine models of skin reaction, lung function and inflammation. Internat Arch Allergy Immunol 1997, 113:231-235. Evidence that the anti-mouse IgE antibody 1-5 in the mouse model induced inhibition of symptoms relating to skin allergies and allergic asthma such as antigen-induced skin reactions, bronchoconstriction, bronchial hyperreactivity and pulmonary eosinophilic inflammation.
44. Coyle AJ, LeGros G, Bertrand C, Tsukuki S, Heusser CH, Kopf M, Anderson G: IL-4 is required for the induction of lung Th2 mucosal immunity. Respir Cell Mol Biol 1995, 13:54-59.
45. + lymphocytes and interleukin-5 mediate antigen induced eosinophil infiltration into the mouse trachea. Am Rev Respir Dis 1992, 144:374-379.
46. Colye AJ, Wagner K, Bertrand C, Tsuyuki S, Bews J, Heusser CH: Central role of immunoglobulin E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody. J Exp Med 1996, 183: 1303-1310. First demonstration that antigen-induced infiltration of eosinophils into the lung in a mouse model of allergic asthma is mediated by an IgE-dependent mechanism that operates via an IgE-FcεRII interaction provoking enhanced Th2 cytokine production by lung T cells. Evidence that this pulmonary inflammatory response can be inhibited by an non-anaphylactogenic and anti-IgE antibody.
47. Kehry MR, Yamashita LC: Low affinity IgE receptor (CD23) function on mouse B cells: role in IgE dependent focusing. Proc Natl Acad Sci USA 1989, 86:7556-7560.
48. Coyle AJ, Eum S-Y, Lefort J, Heusser C, Vargaftig B: Central role of IgE in antigen induced brochoconstriction, eosinophil accumaulation and airway hyperreactivity: inhibition by a non-anaphylactogenic anti-IgE monoclonal antibody. Am J Resp Crit Care Med 1996, 153:A217.
49. Saban R, Haak-Frendscho M, Zine M, Ridgway J, Gorman C, Presta LG, Bjorling D, Saban M, Jardieu P: Human FcεRI-IgG and humanized anti-IgE monoclonal antibody MaE11 block passive sensitization of human and rhesus monkey lung. J Allergy Clin Immunol 1994, 94:836-843.
50. Marshall JS, Wells PD, Bell EB: Accelerated elimination of N. brasiliensis from the small intestine after auto-anti-IgE induction. Immunology 1987, 60:303-308.
51. Amiri P, Haak-Frendscho M, Robbins K, McKerrow JH, Stewart T, Jardieu P: Anti-immunoglobulin E treatment decreases worm burden and egg production in Schistosoma mansoni-infected normal and interferon knockout mice. J Exp Med 1994, 180:43-51.
52. Magnusson CGM, Johansson SGO: Clinical significance of anti-IgE autoantibodies and immune complexes containing IgE. Clin Rev Allergy 1989, 7:73-103.
53. Czech W, Stadler BM, Schopf E, Kapp A: IgE autoantibodies in atopic dermatitis-occurrence of different antibodies against the CH3 and the CH4 epitopes of IgE Allergy 1995, 50:243-248.
54. Yu Y, de Weck AL, Stadler BM, Muller U: Anti-IgE autoantibodies and bee-sting allergy. Allergy 1995, 50:119-125.
55. Stadler BM: Anti-IgE autoantibodies in asthma: a diagnostic artefact or an explanation for non-allergic asthma? Rev Med Suisse Romande 1994, 114:199-201.
56. Tong LJ, Balakrishnan G, Kochan JP, Kinet JP, Kaplan AP: Assessment of autoimmunity in patients with chronic urticaria. J Allergy Clin Immunol 1997, 99:461-465.
57. Stadler BM, Rudolf MP, Zurcher AW, Miescher S, Vogel M: Anti-IgE in allergic sensitization. Immunol Cell Biol 11996, 74:195-200.
58. Kolbinger F, Saldanha J, Hardman N, Mendig MM: Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies. Prot Eng 1993, 6:971-980.
59. Presta L, Lahr S, Shields R, Porter J, Gorman C, Fendly B, Jardieu P: Humanization of an antibody directed against immunoglobulin E J Immunol 1993, 151:2623-2632.
60. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT: Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984, 81:6851-6855.
61. Reichmann L, Clark M, Waldmann H, Winter G: Reshaping human antibodies for therapy. Nature 1988, 332:323-327.
62. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G: Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986, 321:522-525.
63. Amit AG, Mariuzza FRA, Phillips SEVO, Poljak RJ: Three-dimensional structure of an antigen-antibody complex at 2.8 Å resolution. Science 1986, 233:747-753.
64. Carter P, Presta L, German CM, Ridgway JBB, Henner D, Wong WLT, Rowland AM, Kotts C, Carver ME, Shepard MH: Humanization of an anti-p185 HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992, 89:4285-4289.
65. Shields R, Werther W, Zioncheck K, O'Connell L, Fendly B, Presta L, Thomas D, Saban R, Jardieu P: Inhibition of allergic reactions with antibodies to IgE. Proceedings 20th Symposium Collegium Internationale Allergologicum (eds S. Galli and D. Sheffer) 1995, 107:308-312.
66. Fox JA, Hotaling TE, Struble C, Ruppel J, Bates DJ, Schoenhoff MB: Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Therap 1996, 279:1000-1008.
67. Meng YG, Singh N, Wong WL: Binding of cynomolgus monkey IgE to a humanized anti-human IgE antibody and human high affinity IgE receptor. Mol Immunol 1996, 33:635-642.
68. Corne J, Djukanovic R, Thomas L, Warner J, Botta L, Grandordy B, Gygax D, Heusser C, Patalano F, Richardson W et al.: The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: Efficacy, safety and pharmacokinetics. J Clin Invest 1997, 99:879-887. Phase I study with CGP 51901 demonstrates that anti-IgE therapy is well tolerated and decreases serum free IgE levels in a dose-dependent manner.
69. Malveaux FJ, Conroy MC, Adkinson NFJ, Lichtenstein LM: IgE receptors on human basophils: Relationship to serum IgE concentration. J Clin Invest 1978, 62:176-XXX.
70. MacGlashan Jr D, Bochner B, Adelman D, Jardieu P, Togias A, McKenzie-White J, Sterbinsky S, Hamilton R, Lichtenstein L: Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997, 158:1438-1445. Evidence that reduction in serum IgE levels correlates with reduction of levels of FcεRI receptor expression on human basophils.
71. Yamaguchi M, Lantz CS, Oettgen HC, Katona IM, Fleming T, Miyajima I, Kinet JP, Galli SJ: IgE enhances mouse mast cell FcεRI expression in vitro and in vivo: evidence for a novel amplification mechanism in IgE-dependent reactions. J Exp Med 1997, 185:663-672.
72. Lantz C S, Yamaguchi M, Oettgen HC, Katona IM, Miyajima I, Kinet JP, Galli SJ: IgE regulates mouse basophil FcεRI expression in vivo. J Immunol 1997, 158:2517-2521.
73. Casale TB, Bernstein IL, Busse WW, LaForce CR, Tinkelman DG, Stoltz RR, Dockhorn RJ, Reimann J, Su JQ, Fick RB, Adelman DC: Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997, 100:110-121.
74. Zweiman B: The late phase response: role of IgE, its receptor, and cytokines. Curr Opin Immunol 1993, 5:950-955.
75. Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, Fick RB Jr, Boushey HA: The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Resp Crit Care Med 1997, 155:1828-1834. First demonstration of the potential for clinical efficacy of anti-IgE treatment in allergic asthma.
76. Boulet LP, Chapman KR, Côté J, Kalra S, Bhagat R, Swystun VA, Laviolette M, Cleland LD, Deschesnes F, Su JQ ef al.: Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Resp Crit Care Med 1997, 155:1835-1840. Results of clinical trial reveal significant inhibition of bronchoprovocation response within 30 days of E25 administration.